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A B S T R A C T
Purpose
We report the first-in-human phase Ia study to our knowledge (ClinicalTrials.gov identifier:
NCT01219699) identifying the maximum tolerated dose and assessing safety and preliminary ef-
ficacy of single-agent alpelisib (BYL719), an oral phosphatidylinositol 3-kinase a (PI3Ka)–selective
inhibitor.
Patients and Methods
In the dose-escalation phase, patients with PIK3CA-altered advanced solid tumors received once-
daily or twice-daily oral alpelisib on a continuous schedule. In the dose-expansion phase, patients
with PIK3CA-altered solid tumors and PIK3CA-wild-type, estrogen receptor–positive/human epi-
dermal growth factor receptor 2–negative breast cancer received alpelisib 400 mg once daily.
Results
One hundred thirty-four patients received treatment. Alpelisib maximum tolerated doses were
established as 400mg once daily and 150mg twice daily. Nine patients (13.2%) in the dose-escalation
phase had dose-limiting toxicities of hyperglycemia (n = 6), nausea (n = 2), and both hyperglycemia and
hypophosphatemia (n = 1). Frequent all-grade, treatment-related adverse events included hyper-
glycemia (51.5%), nausea (50.0%), decreased appetite (41.8%), diarrhea (40.3%), and vomiting
(31.3%). Alpelisib was rapidly absorbed; half-life was 7.6 hours at 400 mg once daily with minimal
accumulation. Objective tumor responses were observed at doses $ 270 mg once daily; overall
response rate was 6.0% (n = 8; one patient with endometrial cancer had a complete response, and
seven patients with cervical, breast, endometrial, colon, and rectal cancers had partial responses).
Stable disease was achieved in 70 (52.2%) patients and was maintained. 24 weeks in 13 (9.7%)
patients; disease control rate (complete and partial responses and stable disease) was 58.2%. In
patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative
breast cancer, median progression-free survival was 5.5 months. Frequently mutated genes
($ 10% tumors) included TP53 (51.3%), APC (23.7%), KRAS (22.4%), ARID1A (13.2%), and
FBXW7 (10.5%).
Conclusion
Alpelisib demonstrated a tolerable safety profile and encouraging preliminary activity in patients
with PIK3CA-altered solid tumors, supporting the rationale for selective PI3Ka inhibition in com-
bination with other agents for the treatment of PIK3CA-mutant tumors.
J Clin Oncol 36:1291-1299. © 2018 by American Society of Clinical Oncology
INTRODUCTION
The phosphatidylinositol 3-kinase (PI3K)/
mammalian target of rapamycin (mTOR) path-
way is frequently dysregulated in cancer, often
because of activating mutations or amplification
of PIK3CA (encoding the catalytic p110a subunit
of PI3K).1 PIK3CAmutations are among themost
frequent alterations in solid tumors, identified in
42% to 55% of endometrial,2 42% of cervical,3
27% to 36% of breast,4,5 18% of colorectal,6 13%
of head and neck,7 and 12% of ovarian cancers.8
Targeting the PI3K/mTOR pathway may be
particularly effective in cancers that signal heavily
through PI3Ka, such as those harboring PIK3CA
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alterations.9-12 The clinical development of pan-PI3K and dual
PI3K/mTOR inhibitors has been limited by off-target toxicities
(including GI toxicities, hepatotoxicity, and mood alterations) and
modest clinical activity.13-15 Isoform-specific inhibitors could permit
administration at higher, pharmacologically active doses, with fewer
off-target effects.12,16
Alpelisib (BYL719; Novartis Pharma AG, Basel, Switzerland) is
an oral, selective inhibitor of p110a, with half-maximum inhibitory
concentrations (in vitro biochemical assay) for p110a, b, g, and d of
4.6, 1,156, 250, and 290 nM, respectively.12 Alpelisib has demon-
strated antitumor activity in multiple cancer cell lines and tumor xe-
nograft models, particularly those harboring PIK3CAmutations or
amplifications,12,17 highlighting the potential for enhanced clinical
activity in patients with PIK3CA-altered tumors. We report final
results from a first-in-human dose-escalation and dose-expansion
study, to our knowledge, of single-agent alpelisib in patients with
PIK3CA-altered advanced solid tumors and PIK3CA-altered and
PIK3CA-wild-type estrogen receptor (ER)–positive/human epider-
mal growth factor receptor 2 (HER2)–negative breast cancer.
PATIENTS AND METHODS
Patient Population
This study (ClinicalTrials.gov identifier: NCT01219699) enrolled
patients with tumors harboring PIK3CA mutation and/or amplification,
assessed locally or centrally. To explore whether tumors harboring PIK3CA
alterations weremore sensitive to alpelisib than PIK3CA-wild-type tumors,
the dose-expansion phase also included patients with PIK3CA-wild-type,
ER-positive/HER2-negative, locally advanced or metastatic breast cancer.
Patients age$ 18 years and with Eastern Cooperative Oncology Group
performance status # 2, with histologically confirmed, unresectable, ad-
vanced solid tumors, who had progression of disease per Response Evaluation
Criteria in Solid Tumors (RECIST) version 1.0 on their last line of therapywithin
3 months of screening, or for whom no standard anticancer therapy existed,
were eligible. Patients had at least one measurable or nonmeasurable lesion per
RECIST v1.0 and fasting plasma glucose (FPG), 140 mg/dL (7.8 mmol/L).
Key exclusion criteria included diabetes mellitus (treated and/or symptomatic,
or with FPG $ 140 mg/dL [7.8 mmol/L]), a history of gestational diabetes
mellitus, or documented steroid-induced diabetes mellitus; and failure to
benefit from a prior PI3K, AKT (Protein Kinase B), or mTOR inhibitor.
The study was approved by ethics committees and institutional review
boards of participating institutions and appropriate regulatory authorities; all
patients provided written informed consent. The study was conducted in
accordance with the Declaration of Helsinki and guidelines for GoodClinical
Practice, as defined by the International Conference on Harmonization.
Study Design
This was a phase Ia, multicenter, open-label, dose-escalation study of
single-agent alpelisib with a dose-expansion arm at themaximum tolerated
dose (MTD). The primary objective was to determine the MTD or rec-
ommended phase II dose of oral alpelisib administered in once-daily and
twice-daily regimens. Secondary objectives included assessment of safety
and tolerability, pharmacokinetics (PK), and preliminary efficacy. Ex-
ploratory objectives included characterization of pharmacodynamic ac-
tivity and biomarkers of response to alpelisib.
Patients received oral alpelisib 30 to 450 mg once daily or 120 to
200 mg twice daily on a continuous schedule in 28-day cycles until disease
progression, unacceptable toxicity, withdrawal of consent, or investigator’s
decision. After MTD/recommended phase II dose determination for the
once-daily schedule, an expansion arm was opened to further characterize
safety and assess preliminary efficacy at this dose.
The MTD was defined as the highest dose of alpelisib not causing
a dose-limiting toxicity (DLT) in . 33% of patients during the first
treatment cycle. Dose escalation was guided by an adaptive Bayesian lo-
gistic regression model incorporating the escalation with overdose control
(EWOC) principle.18 Under EWOC, the dose selected as the MTD must
have a , 25% chance that the true DLT rate exceeds 33%, given the
available DLT information. The study data (including DLTs during cycle
1 and other safety and PK data) were reviewed by the sponsor and trial
investigators at each dose level. Intrapatient dose escalation was not permitted
during the first four treatment cycles.
DLTs were defined as adverse events (AEs) or laboratory abnor-
malities possibly related to study treatment (and unrelated to the un-
derlying disease) occurring during the first treatment cycle. DLTs included:
grade$ 2 hyperglycemia (see safety and efficacy assessments for grading);
grade$ 2 photosensitivity; specified grade$ 3 hematologic, renal, hepatic,
metabolic, or subcutaneous AEs lasting for . 7 days; or any other grade
$ 3 toxicity.
Safety and Efficacy Assessments
Routine clinical and laboratory assessments, including hematology
and biochemistry, were conducted at baseline, weekly until cycle 2 day 28,
and then every 2 weeks. Glucose monitoring and other safety assessments
were performed at baseline and regularly throughout the study. AEs were
assessed continuously according to Common Terminology Criteria for
Adverse Events version 4.0; hyperglycemia grading was based on modified
American Diabetes Association criteria: grade 0 (FPG , 140 mg/dL
[, 7.8 mmol/L]); grade 1 (FPG 140 to 199 mg/dL [7.8 to 11.1 mmol/L]);
grade 2 (FPG 200 to 249 mg/dL [11.2 to 13.8 mmol/L], confirmed with
a repeat FPG measurement within 24 hours, and not resolving to grade
0 within 14 days despite intervention with antidiabetic medication such as
glimepiride, glibenclamide, or metformin); grade 3 (FPG 250 to 399 mg/dL
[13.9 to 22.2mmol/L] confirmedwithin 24 hours); grade 4 (FPG$ 400mg/dL
[$ 22.3 mmol/L], confirmed within 24 hours). Serious AEs were defined as
any medical or life-threatening AE resulting in hospitalization or sig-
nificant disability. Radiologic tumor response assessments were per-
formed by computerized tomography or magnetic resonance imaging at
screening, cycle 2 day 28, every 8 weeks thereafter, and at end of treatment.
Overall response rate (ORR), clinical benefit rate (CBR), and disease
control rate (DCR) will be determined. See Data Supplement for phar-
macokinetic profiling.
Biomarker and Pharmacodynamic Assessments
PIK3CA status was assessed by next-generation sequencing (NGS)
using archival or fresh biopsy tissue collected before study start (Data
Supplement). Blood samples for evaluation of glucose metabolism markers
(plasma glucose, insulin, and C-peptide) were collected at baseline; predose and
2 and 4 hours postdose on cycle 1 day 2, cycle 1 day 9, and cycle 2 day 2; and 4 to
6 hours postdose on cycle 2 day 28. Metabolic response was assessed in a subset
of patients by [18F]-fluorodeoxyglucose positron emission tomography.
RESULTS
Patient Characteristics and Disposition
Between October 2010 and March 2014, 134 patients were
enrolled across 11 sites. These included 76 patients in the dose-
escalation phase and 51 patients in the dose-expansion phase with
PIK3CA-altered advanced solid tumors (including two patients with
unconfirmed PIK3CA mutation). There were seven patients with
PIK3CA-wild-type tumors, including five patients with ER-positive/
HER2-negative breast cancer (one in the dose-escalation phase and
four in the dose-expansion phase). Themost common primary cancer
sites were breast (n = 36; 26.9%), colorectal (n = 35; 26.1%), and head
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and neck (n = 19; 14.2%; Table 1). At initial diagnosis, 86 patients
(64.2%) had stage III or IV cancer, and all patients had received prior
antineoplastic therapy.
In total, 108 patients received alpelisib once daily at doses of
30 to 450 mg, including 65 patients at 400 mg once daily; and 26
patients received alpelisib twice daily at doses of 120 to 200 mg,
including 15 patients at 150 mg twice daily. As of February 5, 2015,
130 (97.0%) patients had discontinued treatment: 105 (78.4%)
because of disease progression, 18 (13.4%) because of AEs, three
(2.2%) because of withdrawal of consent, three (2.2%) because of
death (all considered unrelated to study treatment by the in-
vestigator), and one (0.7%) because of administrative problems.
Dose Escalation and Dose-Limiting Toxicities
In the dose-escalation phase, nine of 68 evaluable patients
experienced DLTs. At the highest dose (450 mg once daily), four
of nine patients experienced DLTs of grade 3 nausea or grade 3
hyperglycemia (n = 2 each). No patients treated at # 400 mg once
daily experienced DLTs. At 200 mg twice daily, four of five patients
had dose-limiting hyperglycemia (n = 1 grade 3; n = 3 grade 4). At
150 mg twice daily, one of 10 patients reported hyperglycemia and
hypophosphatemia (both grade 3). The 400 mg once-daily and
150mg once-daily dose levels met the requirements of the Bayesian
logistic regression model–EWOC, having probabilities of 48.4%
and 56.9%, respectively, that the true DLTrate was within the target
toxicity range of 16% to 33% and probabilities of 4.5% and 16.0%,
respectively, that the DLTrate exceeded 33%. Alpelisib single-agent
MTDs were established as 400 mg once daily and 150 mg twice
daily.
DLTs were monitored in the dose-expansion phase to support
the MTD determined by dose escalation. In total, four of 58
evaluable patients receiving alpelisib 400 mg once daily experi-
enced DLTs of grade 4 hyperglycemia (n= 2), grade 3 diarrhea (n= 1),
and grade 3 nausea and grade 3 vomiting (n = 1).
Safety and Tolerability
The most frequent treatment-related AE was hyperglycemia,
an on-target effect of PI3K inhibition,19 reported in 69 (51.5%)
patients across both dosing regimens (32 [23.9%] patients at grade
3 or 4; Table 2). Other treatment-related, all-grade AEs ($ 15% of
patients, any grade) were nausea (50.0%), skin toxicities (42.5%),
Table 1. Patient Characteristics at Baseline
Characteristic All Patients (N = 134)













# 3 57 (42.5)
4-6 63 (47.0)
$ 7 14 (10.4)





NOTE. Data presented as No. (%) unless otherwise noted.
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
*Primary cancer sites classed as other include: cervix (n = 5), lung (n = 5), uterus
(n = 3), bladder, gall bladder, kidney, liver, stomach, pancreas, peritoneum,
thymus (n = 1 each), and other (n = 9).
†Two patientswere enrolledwho did not have PIK3CA status confirmed by local
or central assessment.
Table 2. Adverse Events ($ 15% of patients) Suspected to be Related to Study Treatment
Adverse Event Grade



















Total All 17 (85.0) 7 (87.5) 6 (100) 64 (98.5) 9 (100) 5 (100) 15 (100) 6 (100) 129 (96.3)
3 and 4 2 (10.0) 1 (12.5) 3 (50.0) 33 (50.8) 6 (66.7) 2 (40.0) 6 (40.0) 6 (100) 59 (44.0)
Hyperglycemia All 5 (25.0) 1 (12.5) 2 (33.3) 39 (60.0) 6 (66.7) 2 (40.0) 8 (53.3) 6 (100) 69 (51.5)
3 and 4 0 1 (12.5) 0 17 (26.2) 3 (33.3) 1 (20.0) 5 (33.3) 5 (83.3) 32 (23.9)
Nausea All 6 (30.0) 3 (37.5) 5 (83.3) 35 (53.8) 6 (66.7) 0 8 (53.3) 4 (66.7) 67 (50.0)
3 and 4 0 0 0 1 (1.5) 2 (22.2) 0 0 0 3 (2.2)
Decreased appetite All 4 (20.0) 4 (50.0) 3 (50.0) 29 (44.6) 5 (55.6) 1 (20.0) 6 (40.0) 4 (66.7) 56 (41.8)
3 and 4 0 0 1 (16.7) 2 (3.1) 0 0 0 0 3 (2.2)
Diarrhea All 3 (15.0) 2 (25.0) 3 (50.0) 30 (46.2) 5 (55.6) 2 (40.0) 6 (40.0) 3 (50.0) 54 (40.3)
3 and 4 0 0 0 3 (4.6) 0 0 0 1 (16.7) 4 (3.0)
Vomiting All 6 (30.0) 2 (25.0) 2 (33.3) 24 (36.9) 3 (33.3) 0 2 (13.3) 3 (50.0) 42 (31.3)
3 and 4 0 0 0 3 (4.6) 0 0 0 0 3 (2.2)
Fatigue All 5 (25.0) 2 (25.0) 1 (16.7) 23 (35.4) 3 (33.3) 0 5 (33.3) 1 (16.7) 40 (29.9)
3 and 4 1 (5.0) 0 0 2 (3.1) 1 (11.1) 0 0 0 4 (3.0)
Stomatitis All 0 3 (37.5) 1 (16.7) 13 (20.0) 2 (22.2) 1 (20.0) 5 (33.3) 2 (33.3) 27 (20.1)
3 and 4 0 0 0 1 (1.5) 0 0 0 0 1 (0.7)
NOTE. Data presented as No. (%). All adverse events were characterized and graded per Common Terminology Criteria for Adverse Events v4.0, except for
hyperglycemia, which was graded on the basis of a modified version of the American Diabetes Association accepted criteria.
*# 270 mg group includes patients treated with alpelisib 30, 60, 90, 180, and 270 mg once daily.
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decreased appetite (41.8%), diarrhea (40.3%), vomiting (31.3%),
fatigue (29.9%), and stomatitis (20.1%). Overall, the frequency of
AEs, including fatigue, GI toxicities, weight loss, and dyspnea,
increased slightly with prolonged treatment. The rate of grade 3 or
4 hyperglycemia, rash, and liver toxicities was stable between cycle
1 and later cycles, and the AE profile was consistent throughout the
study (Data Supplement).
Hyperglycemia increased in a dose-dependent manner but was
effectively managed, by dose interruption/reduction or by concom-
itant oral antidiabetic medication (metformin), and in some cases
with the addition of insulin; only six (4.5%) patients permanently
discontinued study treatment because of hyperglycemia. Treatment-
related skin toxicities mainly comprised mild to moderate erythema-
tous or maculopapular rash. Rash was dose dependent and typically
occurred during the first 2 weeks of treatment. Skin toxicities were
managed by concomitant antihistamines or corticosteroids; 12 (9.0%)
patients required dose interruption/reduction because of skin toxicities,
and one (0.7%) patient permanently discontinued treatment because
of hypersensitivity.
In total, 51 (38.1%) patients had at least one dose reduction;
most were in line with protocol-specified guidelines due to AEs. At
the MTDs, dose reductions occurred in 27 of 65 (41.5%) patients
starting at 400 mg once daily and nine of 15 (60.0%) patients
starting at 150 mg twice daily. Dose interruptions were required by
78 (58.2%) patients, of which 63 (47.0%) were due to AEs; dose
interruptions occurred in 40 of 65 (61.5%) patients at 400 mg once
daily and 11 of 15 (73.3%) patients at 150 mg twice daily. Median
exposure to alpelisib was 11.9 (0.4 to 145.4) weeks; 9.6 (1.0 to
145.4) weeks at 400 mg once daily and 13.0 (4.0 to 108.3) weeks at
150 mg twice daily.
Fourteen (10.4%) patients experienced treatment-related
serious AEs; those reported in $ 4% of patients (regardless of
study treatment relationship) were nausea, vomiting, abdominal
pain, dyspnea, hyperglycemia, and pyrexia. None of the 13 (9.7%)
on-treatment deaths were suspected to be treatment-related, and
all were attributed to underlying disease progression (including
one death due to hypoxia).
Pharmacokinetic and Pharmacodynamics Analyses
Alpelisib was rapidly absorbed, with median time to peak
plasma concentrations on cycle 1 day 1 of approximately 2 hours at
both MTDs. The median half-life of alpelisib was 7.6 (4.6 to 27.1)
hours at 400mg once daily. Alpelisib PK profiles and exposure were
consistent on cycle 1 day 1, cycle 1 day 8, and cycle 2 day 1,
suggesting minimal drug accumulation with repeated dosing (Fig 1;
Data Supplement). Systemic exposure to alpelisib at both dosing
schedules seemed to be dose-proportional within the range tested
(Data Supplement). Interpatient variability at steady state for the
once-daily dosing schedule was moderate, with mean coefficient of
variation 17% to 43% for peak serum concentration and 16% to
41% for total exposure (area under the curve 0 to 24 hours), and was
higher with twice-daily dosing, with mean coefficient of variation
37% to 54% for peak serum concentration and 26% to 40% for area
under the curve 0 to 12 hours.
Plasma glucose, insulin, and C-peptide levels weremonitored as
pharmacodynamic markers of glucose regulation, because cellular
glucose uptake is tightly regulated by PI3Ka.19 There was a dose-
dependent increase in maximum fold change in FPG during cycle 1,
starting from 180 mg once daily, with the most pronounced increase
observed at doses higher than the MTDs (Fig 2A). Dose-limiting
hyperglycemia was reported in seven patients. Similar increases were
observed for insulin and C-peptide (Figs 2B and 2C). A decrease in
glucose uptake measured by [18F]-fluorodeoxyglucose positron
emission tomography was observed at doses $ 180 mg once daily
(Fig 2D), with the first partial metabolic response occurring on cycle
1 day 24.
Time Point (hours)
Cycle 2 day 1Cycle 1 day 8Cycle 1 day 1

































Fig 1. Alpelisib geometric mean plasma
concentration–time profiles.
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Clinical Activity and Biomarker Analysis
Best tumor response per RECIST v1.0 was available for 115 of
134 patients; 19 patients were not evaluable, mainly because of
missing postbaseline assessments (for example, if patients dis-
continued before the first on-treatment scan or if they did not have
measurable disease). Objective responses were observed after two
to six treatment cycles at doses of $ 270 mg once daily, with signs
of tumor growth suppression at doses $ 180 mg once daily. ORR
was 6.0%. One patient with endometrial cancer achieved a com-
plete response (CR) at 150 mg twice daily. Partial responses (PRs)
were observed in seven patients: cervical (n = 3), breast, endo-
metrial, colon, and rectal cancers (n = 1 each; Table 3). Stable
disease (SD) was observed in more than half of patients (52%;
n = 70); 13 patients (9.7%) had SD for . 24 weeks. No clinical
benefit was observed in the four patients with PIK3CA-wild-type
ER-positive/HER2-negative breast cancer in the dose-expansion
arm.
Across all tumor types, the CBR (CR + PR + SD. 24 weeks)
was 15.7%, and the DCR (CR + PR + SD) was 58.2%. DCR was
highest in patients with ER-positive/HER2-negative breast cancer
(14 of 23 [60.9%] patients), head and neck cancer (13 of 19
[68.4%]), and cervical cancer (five of five [100.0%]). CBR for
patients with ER-positive/HER2-negative breast cancer was 17.4%
(four of 23 patients). DCR and CBR in patients with colorectal










































































































































































































































































































































































































Fig 2. Maximum fold increase from baseline in (A) fasting plasma glucose, (B) fasting serum insulin, and (C) fasting serum C-peptide during cycle 1, and (D) best
percentage change from baseline in sum of maximum standardized uptake values (sSUVmax) measured by [18F]-fluorodeoxyglucose positron emission tomography.
X represents the geometric mean value.
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Of the 114 patients with tumor volume assessments, 55 (48.2%)
patients achieved some degree of tumor shrinkage (Fig 3). Signs of
increased activity were detected in patients with advanced breast cancer,
with 15 of 27 (55.6%) achieving tumor shrinkage, mostly among those
with PIK3CA-mutant ER-positive/HER2-negative disease, and two
achieving tumor shrinkage of 25.0% and 23.5% (Data Supplement).
Similarly, tumor shrinkagewas observed in patients with ovarian (six of
14 [42.9%]) and head and neck tumors (seven of 17 [41.2%]). Among
22 patients with ER-positive/HER2-negative advanced breast cancer
treated at $ 270 mg once daily, median progression-free survival was
5.5 months (95% CI, 3.0 to 7.0).
In addition to PIK3CAmutation status being measured locally
during screening, tumor samples from 76 patients were also an-
alyzed centrally by NGS (Data Supplement); PIK3CA mutations
were confirmed in 64 of 76 (84.2%) tumors. Frequently mutated
genes ($ 10% of tumors) were TP53 (51.3%), APC (23.7%), KRAS
(22.4%), ARID1A (13.2%), and FBXW7 (10.5%). PTENmutations
(which may contribute to PI3K inhibitor resistance)20 were de-
tected in five patients, including three whose disease progressed
during the first two treatment cycles. Concomitant KRAS muta-
tions were detected in 13 of 17 (76.5%) colorectal tumors, but none
in breast tumors (Data Supplement). Because of the heterogeneous
patient population, a robust analysis of NGS results and tumor
response was not possible.
DISCUSSION
We report a first-in-human study, to our knowledge, evaluating the
safety, MTD, and preliminary efficacy of single-agent alpelisib,
a potent and highly specific p110a inhibitor, in patients with
PIK3CA-altered tumors. Alpelisib demonstrated a favorable safety
profile up to the MTDs of 400 mg once daily and 150 mg twice
daily. At equivalent total daily doses (400 mg once daily and 200mg
twice daily), the once-daily regimen was better tolerated. Overall,
single-agent alpelisib demonstrated a wide therapeutic window,
with significant pharmacodynamic effects and disease stabilization
at $ 180 mg once daily, and objective activity at $ 270 mg once
daily, both well below the MTD of 400 mg once daily. On the basis
of improved tolerability and similar efficacy compared with 400mg
once daily, 300 mg once daily was selected as the dose in the phase
III trial of fulvestrant with or without alpelisib (SOLAR-1; ClinicalTrials.
gov identifier: NCT02437318).
Hyperglycemia was the most frequent DLT and was an an-
ticipated on-target effect related to the role of PI3Ka in insulin
signaling and glucose homeostasis; it was managed per guidance
provided by Busaidy et al19,21 for this class of inhibitors. Indeed,
serial monitoring of plasma glucose, insulin, and C-peptide levels
revealed a dose-dependent increase in all three markers. Of 134
patients, only two permanently discontinued treatment during cycle 1
because of hyperglycemia (both grade 4), with a further four patients
discontinuing during later cycles, reflecting effective management by
dose interruptions and concomitant antidiabetic medications. Pre-
treatment patient characteristics andmetabolic factors associated with
hyperglycemia are under investigation. Other frequent AEs (including
GI toxicities, fatigue, and rash) were effectively managed by standard
supportive care and concomitant antihistamines or corticosteroids.
Eight patients have received treatment of at least 1 year, demonstrating
the long-term tolerability of alpelisib.
This study provides evidence of clinical activity of alpelisib
in a subset of PIK3CA-altered tumors. The ORR in ER-positive/
HER2-negative breast cancer was 4.3%, and these patients expe-
rienced the highest CBR (17.4%) and a high DCR (60.9%)
compared with other cancer types. Although alpelisib single-agent
activity was moderate in this group of patients, the combination of
alpelisib with letrozole in patients with ER-positive/HER2-negative
breast cancer resulted in an ORR of 19% and CBR of 35%22; CBR
was higher in PIK3CA-altered versus PIK3CA-wild-type tumors
(44% v 20%, respectively) in this study. In addition, translational
research indicates the potential mechanistic synergy of combining
PI3K inhibitors and endocrine therapies, particularly for patients with
activating mutations of PIK3CA.23,24 Taken together, these findings
highlight potential treatment benefits of alpelisib, either as a single
agent or in combination with endocrine therapy, in PIK3CA-altered
ER-positive/HER2-negative breast cancer. Moreover, modest single-
agent activity is not uncommon in early studies of targeted agents
in a heterogeneous patient population with multiple prior lines
of therapy.25 Furthermore, PIK3CA mutation status at enrollment











CR* 1 0 0 0
PR† 7 1 0 2
SD 70 13 13 10
Progressive disease 37 6 3 19
Unknown 19 3 3 4
Overall response rate (CR + PR), No. (%) 8 (6.0) 1 (4.3) 0 2 (5.7)
95% CI 2.6 to 11.4 0.1 to 21.9 0.7 to 19.2
Disease control rate (CR + PR + SD), No. (%) 78 (58.2) 14 (60.9) 13 (68.4) 12 (34.3)
95% CI 49.4 to 66.7 38.5 to 80.3 43.4 to 87.4 19.1 to 52.2
Clinical benefit rate (CR + PR + SD . 24 weeks), No. (%) 21 (15.7) 4 (17.4) 2 (10.5) 3 (8.6)
95% CI 10.0 to 23.0 5.0 to 38.8 1.3 to 33.1 1.8 to 23.1
Abbreviations: CR, complete response; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, partial response; RECIST, Response Evaluation
Criteria in Solid Tumors; SD, stable disease.
*CR was observed in one patient with endometrial cancer.
†Other PRs were observed in one patient with endometrial cancer and three patients with cervical cancer.
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was determined locally in archival tissue, which may not provide an
accurate assessment of tumor molecular status because of the spa-
tiotemporal heterogeneity of PIK3CA mutations in tumors.26-28 In-
deed, PIK3CA alterations were confirmed centrally by NGS in only
84.2% of locally positive samples, suggesting tumor heterogeneity or
differences in sequencing methods. Interestingly, exploratory analyses
of BELLE-2 (a phase III study of fulvestrant with or without the pan-
PI3K inhibitor buparlisib) revealed a predictive value forPIK3CA status
in circulating tumor DNA collected immediately before treatment
start.29 The ongoing SOLAR-1 trial includes biomarker analyses to
evaluate circulating tumor DNA PIK3CA status as a tool to identify
patients who might derive increased benefit from alpelisib combi-
nation treatment.
Our analysis of the overall genomic landscape reveals the
frequent presence of multiple concomitant oncogenic alterations in
addition to PIK3CA. Preclinical studies in ovarian cancer have
shown that both PIK3CA mutation and loss of phosphatase and
tensin homolog (PTEN) are required to drive tumor growth.30
Moreover, clinical studies suggest that KRAS mutations might
confer resistance to PI3K/mTOR pathway inhibitors in PIK3CA-
mutant tumors.31 Interestingly, we found that breast tumors
exhibited fewer alterations with an absence of KRASmutations and
more promising clinical activity. Meanwhile, concomitant KRAS
mutations were detected in . 76.5% of colorectal tumors, which
points toward a potential mechanism of resistance to PI3K in-
hibitors, illustrated by the lesser clinical benefit in these patients.
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Primary site of cancer Breast Colorectal Head and neck Ovarian Other
Fig 3. Best percentage change in sum of longest diameters according to (A) study treatment dose, (B) primary site of cancer and metformin treatment, and (C) centrally
obtained next-generation sequencing results. Dummy sample numbers for each patient correspond with the next-generation sequencing results in the Data Supplement.
Of 12 patients with $ 30% reduction in tumor size, complete response (demonstrated with two or more scans taken at least 1 month apart) was observed in one patient
with endometrial cancer. However, overall response was lower because some patients experienced rapid disease progression. A partial response was observed in one
patient with breast cancer, two patients with colorectal cancer, and four patients with other cancers (one patient with endometrial cancer and three patients with cervical
cancer). Stable disease was observed in one patient with ovarian cancer, two patients with head and neck cancer, and one patient with breast cancer. (*) Patients with no
postbaseline assessment for target lesions or patients with only nontarget lesions were excluded. (†) Patients receiving metformin for hyperglycemia.
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Even in the absence of concomitant alterations at treatment ini-
tiation, PIK3CA-mutant breast tumors may develop resistance to
PI3Ka inhibition via increased dependency on PI3Kb,32 upre-
gulation of ER pathway signaling23 or acquisition of a variety of
alterations leading to PTEN loss.20 In the future, sustained disease
control might be achieved through further molecular character-
ization to identify PIK3CA-dependent tumors and avoid those with
concomitant KRAS or PTEN alterations, or by combinatorial
approaches, such as addition of alpelisib to endocrine therapies.
Although the sample size was small, patients with PIK3CA helical
domain mutations (E545K or E542K), unusual kinase mutations
(eg T1052K), or PTEN loss had partial or complete response,
whereas no responses were observed in patients with kinase
mutations on H1047. However, differential activity of alpelisib in
helical versus kinase mutants cannot be accurately determined in
such a heterogeneous set of samples, because the analysis is heavily
confounded by an unequal number of patients in each disease type,
cell lineage effects, and/or concomitant mutations.
In summary, this first-in-human study, to our knowledge,
demonstrates that alpelisib has a favorable safety profile with pre-
dictable PK characteristics. Encouraging signs of antitumor activitywere
observed in patients with PIK3CA-mutant, ER-positive/HER2-negative
breast cancer and other PIK3CA-altered advanced solid tumors. MTD
in this phase Ia study is determined on the basis of the tolerability profile
of this agent during the first cycle of treatment, using widely accepted
safety boundaries for single-agent dose-escalation studies. Since we
observed single-agent activity at $ 270 mg, a subsequent phase Ib
study tested both 300-mg and 400-mg doses in combination with
fulvestrant, with special attention to long-term tolerability of this
agent in patients with breast cancer.33 This phase Ib study was
used to inform the dose for subsequent phase III trials. Ongoing
studies are evaluating alpelisib in combination with endocrine
therapy and other targeted anticancer agents in a range of tumor
types.
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